338840 — Y Biologics Balance Sheet
0.000.00%
- KR₩365bn
- KR₩342bn
- KR₩6bn
Annual balance sheet for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | — | — | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 16,948 | 12,983 | 20,898 | 12,204 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 2,083 | 895 | 639 | 194 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 19,845 | 18,034 | 21,763 | 12,471 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 16,824 | 10,801 | 8,009 | 7,407 |
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 38,245 | 29,323 | 30,294 | 21,727 |
| Accounts Payable | ||||
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 6,209 | 16,195 | 5,508 | 2,444 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 9,803 | 17,029 | 6,886 | 3,371 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| ESOP Debt Guarantee | ||||
| Other Equity | ||||
| Total Equity | 28,441 | 12,293 | 23,408 | 18,356 |
| Total Liabilities & Shareholders' Equity | 38,245 | 29,323 | 30,294 | 21,727 |
| Total Common Shares Outstanding | ||||
| Total Preferred Shares Outstanding |